Renal cell carcinoma in a 36-year-old female: a case report.

Ndu Victor Onyebuchi1*, Pedro Emem Chioma2, Ujah Terhide1
1Department of Internal Medicine, Federal Medical Centre, Yenagoa, Bayelsa State, Nigeria.
2Department of Internal Medicine, University of Port Harcourt Teaching Hospital, Port Harcourt, Rivers State, Nigeria.
*Correspondence: Dr. Ndu Victor Onyebuchi; +234 806 302 3974;

Download full article in pdf format


Background: Renal cell carcinoma is rare in Africa including Nigeria though it accounts for the majority of the malignant renal tumour in our environment. In a 10-year review of all malignant renal tumours in Nigerian hospitals, renal cell carcinoma accounted for 72.2%. In the University College Hospital Ibadan in a 5-year clinico-pathologic review, renal cell carcinoma accounted for 59.5% of all renal masses. It accounts for 2 – 3% of all cancers worldwide.
Case Presentation: She presented with abdominal swelling, weight loss and recurrent abdominal pain of four-year dura on. She was diagnosed of renal cell carcinoma following abdominal CT scan. She had presented earlier to a private hospital at the start of the illness from where she was referred to our centre, but she defaulted and resorted to herbal remedies. She however presented to us 4 years later due to persistent of symptoms. A diagnosis of metastatic renal cell carcinoma was made following contrast- enhanced CT. She was placed on palliative care but died on the 7th day of admission.
Conclusion: The finding of a renal mass should be promptly diagnosed and managed appropriately, and patients should be advised to seek appropriate measures of management after being adequately educated on their diagnosis and likely prognosis.

Keywords: Renal cell carcinoma, Renal mass.

Cite this article: Ndu VO, Pedro EC, Ujah T. Renal cell carcinoma in a 36-year-old female: a case report. Yen Med J. 2020;2(1):193–196.


  1. Badmus TA, Sanusi AA, Arogundade FA, Adesunkanmi ARK, Oyebamiji. Malignant renal tumour in adults: a ten-year review in a Nigerian hospital. Saudi J Kidney Dis Transpl. 2008;19:120-126.
  2. Takure AO, Shittu OB, Adedayo SA, Okolo CA, Sotunmbi PT. Renal cell carcinoma in Ibadan: a 5-year clinicopathologic review. Afri J Med Sci. 2013;42(3):239-243.
  3. Motzer RJ, Bander NH, Nanus DM: Renal cell carcinoma. N Engl J Med. 1996;335(12):865- 875.
  4. Washecka R, Hanna M. Malignant renal tumours in tuberous sclerosis. Urology. 1991;37:340-345.
  5. Chow WH, McLaughlin JK, Linet MS, Niwa S, Mandel JS. Use of analgesics and risk of renal cell cancer. Int J Cancer. 1994;59(4):467-70. doi: 10.1002/ijc.2910590406.
  6. Paganini-Hill A, Henderson BE, Ross RK. Epidermiology of kidney cancer. In: Skinner DG, ed. Urological cancer. New York, USA: Grune and Stratton; 1985:383-407.
  7. Kiely JM. Hypernephroma: the internist tumour. Med Clin North Am. 1966;50:1067-1084.
  8. Curr NS. Small renal masses (lesions smaller than 3 cm): Imaging evaluation and management. Am J Roentgenol. 1995;164:355-359.
  9. Macari M, Bosniak MA. Delayed CT to evaluate renal masses incidentally discovered at contrast enhanced CT: Demonstration of vascularity with deenhancement. Radiol. 1999;213:674-679.
  10. Gold PJ, Thompson JA, Markowitz DR. Metastatic renal cell carcinoma: long-term survival after therapy with high-dose continuous infusion interleukin-2. Cancer J Sci Am. 1997;3:585-591.
  11. Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Fyfe G. High-dose aldesleukin in renal cell carcinoma: long-term survival update. Cancer J Sci Am. 1997;3Suppl 1:S70-S72.
× Chat